MC4R and obesity disorder: Despite advances in pharmacotherapy such as the approval of liraglutide, a glucagon-like peptide (GLP-1) analogue, and setmelanotide, an MC4R agonist, for use in the pediatric population and the improvement in the techniques of bariatric surgery towards the management of obesity during adolescence, multidisciplinary lifestyle intervention programs remain the first-line treatment.